tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

IONS Stock Latest News

AMZN, BABA, NTLA, XYZ: Cathie Wood Loads Up on Intellia, Block, Amazon & Alibaba, Cuts Stake in Shopify and Other Growth Stocks
Market NewsAMZN, BABA, NTLA, XYZ: Cathie Wood Loads Up on Intellia, Block, Amazon & Alibaba, Cuts Stake in Shopify and Other Growth Stocks
19m ago
XYZ
AMZN
Ionis Pharmaceuticals’ Phase 3 Study on Angelman Syndrome: A Potential Game-Changer
PremiumCompany Announcements
Ionis Pharmaceuticals’ Phase 3 Study on Angelman Syndrome: A Potential Game-Changer
4h ago
IONS
Ionis Pharmaceuticals Advances in MECP2 Duplication Syndrome Treatment
PremiumCompany Announcements
Ionis Pharmaceuticals Advances in MECP2 Duplication Syndrome Treatment
5h ago
IONS
Ionis Pharmaceuticals’ HALOS Study: A New Hope for Angelman Syndrome
PremiumCompany Announcements
Ionis Pharmaceuticals’ HALOS Study: A New Hope for Angelman Syndrome
6h ago
IONS
Ionis Pharmaceuticals’ Olezarsen Study: A Potential Game-Changer for Severe Hypertriglyceridemia
PremiumCompany Announcements
Ionis Pharmaceuticals’ Olezarsen Study: A Potential Game-Changer for Severe Hypertriglyceridemia
8h ago
IONS
Ionis Pharmaceuticals’ Rocket Study: Advancing Research in Rare Disease Treatment
PremiumCompany AnnouncementsIonis Pharmaceuticals’ Rocket Study: Advancing Research in Rare Disease Treatment
8h ago
IONS
Ionis Pharmaceuticals’ Orbit Study: A Promising Step for Rare Disease Treatment
Premium
Company Announcements
Ionis Pharmaceuticals’ Orbit Study: A Promising Step for Rare Disease Treatment
9h ago
IONS
Ionis Pharmaceuticals’ ION464 Study: A Potential Breakthrough for Multiple System Atrophy
Premium
Company Announcements
Ionis Pharmaceuticals’ ION464 Study: A Potential Breakthrough for Multiple System Atrophy
10h ago
IONS
IONS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
IONS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
18h ago
IONS
Ionis Pharmaceuticals price target raised to $90 from $86 at Morgan Stanley
PremiumThe Fly
Ionis Pharmaceuticals price target raised to $90 from $86 at Morgan Stanley
12d ago
IONS
Intel, FedEx downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Intel, FedEx downgraded: Wall Street’s top analyst calls
20d ago
EW
CEG
Ionis Pharmaceuticals: Promising Financial Outlook and Strategic Advancements Drive Buy Rating
PremiumRatings
Ionis Pharmaceuticals: Promising Financial Outlook and Strategic Advancements Drive Buy Rating
20d ago
IONS
Ionis Pharmaceuticals: Promising Pipeline and Strong Financial Outlook Justify Buy Rating
PremiumRatingsIonis Pharmaceuticals: Promising Pipeline and Strong Financial Outlook Justify Buy Rating
20d ago
IONS
Ionis Pharmaceuticals price target raised to $90 from $84 at Oppenheimer
Premium
The Fly
Ionis Pharmaceuticals price target raised to $90 from $84 at Oppenheimer
20d ago
IONS
Ionis Pharmaceuticals: Advancements and Catalysts Drive Buy Rating
Premium
Ratings
Ionis Pharmaceuticals: Advancements and Catalysts Drive Buy Rating
20d ago
IONS
Promising Outlook for Ionis Pharmaceuticals: Buy Rating Backed by Pipeline Advancements and Strategic Focus
PremiumRatings
Promising Outlook for Ionis Pharmaceuticals: Buy Rating Backed by Pipeline Advancements and Strategic Focus
20d ago
IONS
Ionis Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
PremiumThe Fly
Ionis Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
20d ago
IONS
Ionis Pharmaceuticals: Upgraded to Buy Amid Promising Pipeline and Market Expansion
PremiumRatings
Ionis Pharmaceuticals: Upgraded to Buy Amid Promising Pipeline and Market Expansion
20d ago
IONS
Ionis Pharmaceuticals price target raised to $67 from $43 at Stifel
PremiumThe Fly
Ionis Pharmaceuticals price target raised to $67 from $43 at Stifel
22d ago
AZN
IONS
Private Markets: Cerebras raises $1B in pre-IPO funding round
PremiumThe FlyPrivate Markets: Cerebras raises $1B in pre-IPO funding round
24d ago
IBM
NET
Ionis Pharmaceuticals: Strategic Advancements and Market Opportunities Amidst Competitive Challenges
Premium
Ratings
Ionis Pharmaceuticals: Strategic Advancements and Market Opportunities Amidst Competitive Challenges
29d ago
IONS
CarMax downgraded, Kenvue upgraded: Wall Street’s top analyst calls
Premium
The Fly
CarMax downgraded, Kenvue upgraded: Wall Street’s top analyst calls
1M ago
V
V

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >